Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 1,101–1,200 of 2,576
Biomarkers in the Diagnosis and Prognosis of Alzheimer’s Disease
Schaffer, C., Sarad, N., DeCrumpe, A., Goswami, D., Herrmann, S., Morales, J., Patel, P., & Osborne, J. (2014) · SLAS TECHNOLOGY · doi:10.1177/2211068214559979 · Cited by 51
Neuroimaging Results Impose New Views on Alzheimer’s Disease—the Role of Amyloid Revised
Fjell, A. M., & Walhovd, K. B. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8228-7 · Cited by 53
“Aβ accumulation in AD may be more related to decreased clearance than increased production in the sporadic form of AD [103, 104], in contrast to evidence pointing to increased Aβ production in familial AD [105].”
ResultStructure, mechanism and inhibition of γ-secretase and presenilin-like proteases
Wolfe, M. S. (2010) · Biological Chemistry · doi:10.1515/bc.2010.086 · Cited by 56
“The diseasecausing missense mutations were found to alter how g-secretase cuts APP, leading to increased proportions of longer, more aggregation-prone forms of Ab (Duff et al., 1996; Lemere et al., 1996; Scheuner et al., 1996; Citron et al., 1997).”
Meng, F., Dai, E., Yu, X., Zhang, Y., Chen, X., Liu, X., Wang, S., Wang, L., & Jiang, W. (2014) · Journal of The Royal Society Interface · doi:10.1098/rsif.2013.1057 · Cited by 48
Drosophila Signal Peptide Peptidase Is an Essential Protease for Larval Development
Casso, D. J., Tanda, S., Biehs, B., Martoglio, B., & Kornberg, T. B. (2005) · Genetics · doi:10.1534/genetics.104.039933 · Cited by 52
Neuroimaging and the Search for a Cure for Alzheimer Disease
Petrella, J. R. (2013) · Radiology · doi:10.1148/radiol.13122503 · Cited by 52
Sheikh, A. M., & Nagai, A. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07984.x · Cited by 47
Lee, E., Giovanello, K. S., Saykin, A. J., Xie, F., Kong, D., Wang, Y., Yang, L., Ibrahim, J. G., Doraiswamy, P. M., Zhu, H., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.04.004 · Cited by 60
Jan, A. T., Azam, M., Rahman, S., Almigeiti, A. M. S., Choi, D. H., Lee, E. J., Haq, Q. M. R., & Choi, I. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00356 · Cited by 47
“…a critical role in the multi-causality of dementia (Boyle et al., 2013), mutations in APP enhance aggregation, while PSEN1&2 mutations cause less efficient APP processing, leading to longer and more hydrophobic Aβs (Scheuner et al., 1996; Chávez-Gutiérrez et al., 2012; Wong et al., 2013; Table 1).”
BackgroundStress and Alzheimer’s disease: A senescence link?
Lyons, C. E., & Bartolomucci, A. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.05.010 · Cited by 56
“Familial early onset forms of AD are caused by mutations in the precursor protein APP, or in the γ-secretase components, presenilin 1 and presenilin 2 (PSEN1, PSEN2), which result in an increased ratio of Aβ42 to Aβ40(Scheuner et al., 1996).”
BackgroundInfluentialEffect of caspase cleavage-site phosphorylation on proteolysis
Tőzsér, J., Bagossi, P., Zahuczky, G., Specht, S. I., Majerová, E., & Copeland, T. D. (2003) · Biochemical Journal · doi:10.1042/bj20021901 · Cited by 47
In vitro processing of amyloid precursor protein by cathepsin D
Sadik, G., Kaji, H., Takeda, K., Yamagata, F., Kameoka, Y., Hashimoto, K., Miyanaga, K., & Shinoda, T. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00053-9 · Cited by 51
Genes and susceptible loci of Alzheimer’s disease
Shastry, B. S., & Giblin, F. J. (1999) · Brain Research Bulletin · doi:10.1016/s0361-9230(98)00156-7 · Cited by 58
Serum levels of albumin‐amyloid beta complexes are decreased in Alzheimer's disease
Yamamoto, K., Shimada, H., Koh, H., Ataka, S., & Miki, T. (2013) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12147 · Cited by 51
Lee, J. H., Chulikavit, M., Pang, D. I., Zigman, W. B., Silverman, W. P., & Schupf, N. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.08.042 · Cited by 48
Energy and the Alzheimer brain
Mamelak, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.001 · Cited by 54
“The great majority of the FAD mutations lso conferred a similar biochemical phenotype with a significant ncrease in the extracellular plasma level of A42 compared to A40 (Borchelt et al., 1996; Scheuner et al., 1996).”
BackgroundNitsch, R. M., Kim, C., & Growdon, J. H. (1998) · Neurochemical Research · doi:10.1023/a:1022423813362 · Cited by 50
Pacheco-Quinto, J., Clausen, D., Pérez-González, R., Peng, H., Meszaros, A., Eckman, C. B., Levy, E., & Eckman, E. A. (2019) · The FASEB Journal · doi:10.1096/fj.201801319r · Cited by 45
Self-citationThe Interaction Between Contactin and Amyloid Precursor Protein and Its Role in Alzheimer’s Disease
Bamford, R. A., Widagdo, J., Takamura, N., Eve, M., Anggono, V., & Oguro‐Ando, A. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.10.006 · Cited by 50
Flavonoid-Based Nanomedicines in Alzheimer’s Disease Therapeutics: Promises Made, a Long Way To Go
Prasanna, P., & Upadhyay, A. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00224 · Cited by 53
Genetic Mouse Models of Neurodegenerative Diseases
Trancikova, A. K., Ramonet, D., & Moore, D. J. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-384878-9.00012-1 · Cited by 54
Loss of presenilin function causes Alzheimer's disease‐like neurodegeneration in the mouse
Chen, Q., Nakajima, A., Choi, S. H., Xiong, X., & Tang, Y. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21601 · Cited by 46
“Indeed, a huge body of evidence has shown that FAD-linked PS1 variants have this abnormal gain-offunction property (Citron et al., 1992; Borchelt et al., 1996; Scheuner et al., 1996).”
BackgroundSun, X., Chiu, C. C., Liebson, E. S., Crivello, N. A., Wang, L., Claunch, J. D., Folstein, M. F., Rosenberg, I. H., Mwamburi, D. M., Peter, I., et al. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31819cb3ac · Cited by 50
Stereochemical specificity of Alzheimer's disease ?-peptide assembly
Esler, W. P., Stimson, E. R., Fishman, J. B., Ghilardi, J. R., Vinters, H. V., Mantyh, P. W., & Maggio, J. E. (1999) · Biopolymers · doi:10.1002/(sici)1097-0282(199905)49:6<505::aid-bip8>3.0.co;2-i · Cited by 51
Rab6 membrane association is dependent of Presenilin 1 and cellular phosphorylation events
Scheper, W., Zwart, R., & Baas, F. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.11.013 · Cited by 55
Blasko, I., Kemmler, G., Krampla, W. W., Jungwirth, S., Wichart, I., Jellinger, K. A., Tragl, K. H., & Fischer, P. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.006 · Cited by 52
Abnormalities in Alzheimer’s Disease Fibroblasts Bearing the APP670/671 Mutation
Gibson, G. E., Vestling, M., Zhang, H., Szolosi, S., Alkon, D., Lannfelt, L., Gandy, S., & Cowburn, R. F. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00149-8 · Cited by 47
Self-citationSynaptic Changes in the Dentate Gyrus of APP/PS1 Transgenic Mice Revealed by Electron Microscopy
Alonso-Nanclares, L., Merino-Serrais, P., Gonzalez, S., & DeFelipe, J. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31828d41ec · Cited by 45
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Langerscheidt, F., Wied, T., Al Kabbani, M. A., van Eimeren, T., Wunderlich, G., & Zempel, H. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12314-3 · Cited by 46
“Mutations in the Amyloid precursor protein (APP), the precursor molecule whose proteolysis generates Aβ [113], or in Presenelin-1 or Presenelin-2, which comprise the catalytic domain of APP-protease γ-secretase [114], lead to increased or aberrant production and accumulation of Aβ-42.”
BackgroundMorphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis
Almeida, Z. L., Vaz, D. C., & Brito, R. M. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04543-4 · Cited by 52
An effective treatment for Alzheimer's disease must consider both amyloid and tau
Lansdall, C. J. (2014) · Bioscience Horizons · doi:10.1093/biohorizons/hzu002 · Cited by 46
“Furthermore, no correlation between increased Aβ42, induced by FAD mutants and age of disease onset was reported (Scheuner et al., 1996).”
BackgroundOf Energy and Entropy: The Ineluctable Impact of Aging in Old Age Dementia
Boccardi, V., Comanducci, C., Baroni, M., & Mecocci, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122672 · Cited by 53
“The first one is present at a younger age, and it is often recognized as due to autosomal dominant inheritance; the latter tends to manifest in the old age, and it is not associated with a deterministic gene mutation, although AD-affected relatives can be detected in the family history [11].”
BackgroundLi, Z., Moniruzzaman, M., Dastgheyb, R. M., Yoo, S., Wang, M., Hao, H., Liu, J., Casaccia, P., Nogueras‐Ortiz, C. J., Kapogiannis, D., et al. (2020) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12035 · Cited by 54
“…begins during the earliest stages of AD concurrent with increased inflammatory markers (Beyreuther & Masters, 1991; RoveletLecrux et al., 2006; Scheuner et al., 1996), it is not clear whether systemic inflammation and/or neuroinflammation during this time directly contributes to the…”
BackgroundAssociation between Sleep, Alzheimer’s, and Parkinson’s Disease
Matsumoto, S., & Tsunematsu, T. (2021) · Biology · doi:10.3390/biology10111127 · Cited by 47
“In addition, mutations in the presenilin (PS) genes PS1 and PS2 have also been identified as causative genes that enhance APP processing to generate toxic forms of Aβ [18].”
BackgroundLiu, L., Lauro, B. M., He, A., Lee, H., Bhattarai, S., Wolfe, M. S., Bennett, D. A., Karch, C. M. M., Young‐Pearse, T. L., Dominantly Inherited Alzheimer Network (DIAN), et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12646 · Cited by 52
Self-citationBorsom, E. M., Conn, K. A., Keefe, C. R., Herman, C., Orsini, G. M., Hirsch, A. H., Avila, M. P., Testo, G., Jaramillo, S. A., Bolyen, E. K., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03458-22 · Cited by 47
A Novel Presenilin-1 Mutation (Leu85Pro) in Early-Onset Alzheimer Disease With Spastic Paraparesis
Ataka, S., Tomiyama, T., Takuma, H., Yamashita, T., Shimada, H., Tsutada, T., Kawabata, K., Mori, H., & Miki, T. (2004) · Archives of Neurology · doi:10.1001/archneur.61.11.1773 · Cited by 45
Mouse models of Alzheimer's disease: The long and filamentous road
Phinney, A. L., Horne, P., Yang, J., Janus, C., Bergeron, C., & Westaway, D. (2003) · Neurological Research · doi:10.1179/016164103101202020 · Cited by 46
Lesuisse, C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.22.2525 · Cited by 46
Presenilin‐1 protein expression in familial and sporadic Alzheimer's disease
Levey, A. I., Heilman, C. J., Lah, J. J., Nash, N. R., Rees, H. D., Wakai, M., Mirra, S. S., Rye, D. B., Nochlin, D., Bird, T. D., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410410610 · Cited by 45
Self-citationRecent Advances in the Genetics of Alzheimer's Disease
Levy‐Lahad, E., Tsuang, D. W., & Bird, T. D. (1998) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879801100202 · Cited by 50
Self-citationAlzheimer's presenilin 1 is a putative membrane receptor for rab GDP dissociation inhibitor
Scheper, W., Zwart, R., van der Sluijs, P., Annaert, W., Gool, W. A., & Baas, F. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.2.303 · Cited by 52
De Jonghe, C., Cras, P., Vanderstichele, H., Cruts, M., Vanderhoeven, I., Smouts, I., Vanmechelen, E., Martin, J.-J., Hendriks, L., & Van Broeckhoven, C. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0247 · Cited by 45
Palacino, J. J., Berechid, B. E., Alexander, P., Eckman, C. B., Younkin, S. G., Nye, J. S., & Wolozin, B. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.215 · Cited by 50
Self-citationSullivan, S. E., Liao, M., Smith, R. V., White, C., Lagomarsino, V. N., Xu, J., Taga, M., Bennett, D. A., De Jager, P. L., & Young-Pearse, T. L. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddy376 · Cited by 44
Petralla, S., Panayotova, M., Franchina, E., Fricker, G., & Puris, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070948 · Cited by 49
“Moreover, mutations in the genes encoding the active site of γ -secretase result in an increased production of A β 1–42 , an A β subspecies with the tendency to self-aggregate faster [29,30].”
BackgroundVandersteen, A., Masman, M. F., Baets, G. D., Jonckheere, W., van der Werf, K., Marrink, . J., Rozenski, J., Benilova, I., Strooper, B. D., Subramaniam, V., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394635 · Cited by 58
“Although quantitative information on the released amounts of the four A isoforms of interest from APP is only available for FAD mutations based on in vitro observations (11, 44, 47, 48), we performed titration assays (Fig.”
MethodDrug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases
Hung, S. S. C., Khan, S., Lo, C. Y.-W., Hewitt, A. W., & Wong, R. C. B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.026 · Cited by 49
Successive cleavage of β-amyloid precursor protein by γ-secretase
Funamoto, S., Tagami, S., Okochi, M., & Morishima‐Kawashima, M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.04.002 · Cited by 48
Age‐related changes of intracellular Aβ in cynomolgus monkey brains
Kimura, N., Yanagisawa, K., Terao, K., Ono, F., Sakakibara, I., Ishii, Y., Kyuwa, S., & Yoshikawa, Y. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2004.00624.x · Cited by 44
Rational heterodoxy: Cholesterol reformation of the amyloid doctrine
Castello, M. A., & Soriano, S. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.007 · Cited by 45
Decreased level of brain acetylcholine and memory disturbance in APPsw mice
Ikarashi, Y., Harigaya, Y., Tomidokoro, Y., Kanai, M., Ikeda, M., Matsubara, E., Kawarabayashi, T., Kuribara, H., Younkin, S. G., Maruyama, Y., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00122-2 · Cited by 49
“Since all mutations in these genes increase the extracellular concentration of A 40 and/or A 42(43) in cultured cells, fibroblasts or plasma from patients and transgenic (Tg) mice expressing FAD-linked mutants [4,8,12,43],”
BackgroundSelf-citationRefolo, L. M., Eckman, C., Prada, C.-M., Yager, D., Sambamurti, K., Mehta, N. D., Hardy, J., & Younkin, S. G. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732383.x · Cited by 51
“First, mutations in PS1 lead to increased synthesis of Ab42 (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997; Holcomb et al., 1998; Mehta et al., 1998), suggesting that these mutations result in an increased amyloidogenic processing of APP.”
BackgroundSelf-citationOshima, N., Morishima‐Kawashima, M., Yamaguchi, H., Yoshimura, M., Sugihara, S., Khan, K., Games, D., Schenk, D., & Ihara, Y. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64693-7 · Cited by 46
Assessing the causes and consequences of co-polymerization in amyloid formation
Sarell, C. J., Stockley, P. G., & Radford, S. E. (2013) · Prion · doi:10.4161/pri.26415 · Cited by 46
Ishii, K., Ii, K., Hasegawa, T., Shoji, S., Doi, A., & Mori, H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00347-9 · Cited by 44
Alzheimer’s disease and sleep disorders: A bidirectional relationship
Chen, J., Peng, G., & Sun, B. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.08.008 · Cited by 47
“In addition, in transgenic mice and cultured cells overexpressing mutant PS1, the changed APP proteolytic processing resulted in both enhanced production of A β 1-42 and lowered level of secreted APP with effects of neuroprotection (Scheuner et al., 1996).”
BackgroundA survey of ABCA1 sequence variation confirms association with dementia
Reynolds, C. A., Hong, M.-G., Eriksson, U. K., Blennow, K., Bennet, A. M., Johansson, B., Malmberg, B., Berg, S., Wiklund, F., Gatz, M., et al. (2009) · Human Mutation · doi:10.1002/humu.21076 · Cited by 41
“Importantly, other genes that are proven to lead to rare familiar forms of AD (APP, PSEN1, and PSEN2) [Goate et al., 1991; Rogaev et al., 1995; Sherrington et al., 1995] have also been shown to be involved in b-amyloid metabolism [Scheuner et al., 1996].”
Toward the structure of presenilin/γ-secretase and presenilin homologs
Wolfe, M. S. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.04.015 · Cited by 51
Aβ 42 /Aβ 40 Ratios of Presenilin 1 Mutations Correlate with Clinical Onset of Alzheimer’s Disease
Tang, N., & Kepp, K. P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180829 · Cited by 47
Prostaglandins as the Agents That Modulate the Course of Brain Disorders
Famitafreshi, H., & Karimian, M. (2020) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s240800 · Cited by 58
“This disease is associated with the accumulation of Amyloidal plaques and Tau tangles in the brain.(118) In most cases, it begins in individuals over 65 years old.”
BackgroundBornebroek, M., De Jonghe, C., Haan, J., Kumar-Singh, S., Younkin, S., Roos, R., & Van Broeckhoven, C. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.019 · Cited by 43
“…been shown that theA PP mutations outside the A region, causing AD, increase the secretion of A 42 with or without a parallel increase in A 40 secretion (Hardy, 1997; Scheuner et al., 1996) Whereas the mutations inside the A region have different effects on the A levels (Nilsberth et al., 2001).”
BackgroundSelf-citationThe relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment
Ma, F., Jianghua, W., Miao, R., Wei, Z., & Wang, Q. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.03.005 · Cited by 55
“Recent evidence further suggests that elevated plasma Aβ may precede the development of the more common sporadic form of AD [5–9].”
BackgroundRingman, J. M., Rao, P. N., Lu, P. H., & Cederbaum, S. (2008) · Archives of Neurology · doi:10.1001/archneur.65.3.412 · Cited by 45
An Update on the Amyloid Hypothesis
Eckman, C. B., & Eckman, E. A. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.007 · Cited by 52
“However, studies performed by Younkin and colleagues [40] showed that in cultured medium from primary fibroblasts and plasma isolated from patients who had either presenilin 1 or presenilin 2 mutations, Ab levels were elevated, in particular Ab42 levels, similar to the 717 mutations in bAPP.”
ResultSelf-citationTranslatability scoring in drug development: eight case studies
Wendler, A., & Wehling, M. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-39 · Cited by 44
“25 [56-59] 0.”
Relation of Plasma Homocysteine to Plasma Amyloid Beta Levels
Luchsinger, J. A., Tang, M.-X., Miller, J. W., Green, R., Mehta, P. D., & Mayeux, R. P. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9207-7 · Cited by 49
“They are also increased in persons with familial AD [12].”
BackgroundClarke, E. E., & Shearman, M. S. (2000) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(00)00280-6 · Cited by 48
Llado-Saz, S., Atienza, M., & Cantero, J. L. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.023 · Cited by 46
“…of Ab 1e40 and Ab 1e42 are increased in familial AD with mutations in the presenilin or the amyloid precursor protein genes (Kosaka et al., 1997; Scheuner et al., 1996) as well as in patients with Down syndrome (Head et al., 2011; Schupf et al., 2001) and in first degree relatives of AD…”
BackgroundZhao, Z., Zhu, L., Bu, X., Ma, H., Yang, S., Yang, Y., & Hu, Z. (2014) · Chemical Communications · doi:10.1039/c4cc07037b · Cited by 47
Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease
Bera, A., Lavanya, G., Reshmi, R., Dev, K., & Kumar, R. K. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15611 · Cited by 45
Role of infection in Alzheimer's disease.
Balin, B. J., & Appelt, D. M. (2001) · PubMed · Cited by 52
Khan, T. K., & Alkon, D. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.07.010 · Cited by 47
Gandhi, S., Refolo, L. M., & Sambamurti, K. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:1:137 · Cited by 48
Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?
Castellani, R. J., Zhu, X., Lee, H., Moreira, P. I., Perry, G. L., & Smith, M. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.5.473 · Cited by 48
Yokota, O., Terada, S., Ishizu, H., Ujike, H., Ishihara, T., Nakashima, H., Yasuda, M., Kitamura, Y., Uéda, K., Checler, F., et al. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0596-7 · Cited by 49
Wolvetang, E. W., Bradfield, O. M., Tymms, M., Zavarsek, S., Hatzistavrou, T., Kola, I., & Hertzog, P. J. (2003) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(03)00121-0 · Cited by 41
Tanii, H., Ankarcrona, M., Flood, F., Nilsberth, C., Mehta, N. D., Pérez‐Tur, J., Winblad, B. G., Benedikz, E., & Cowburn, R. F. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00432-7 · Cited by 45
Vaccines for Alzheimer??s Disease: How Close Are We?
Janus, C. (2003) · CNS Drugs · doi:10.2165/00023210-200317070-00001 · Cited by 49
LDL receptor-related protein (LRP) in Alzheimer's disease: Towards a unified theory of pathogenesis
Van Uden, E., Kang, D. E., Koo, E. H., & Masliah, E. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000815)50:4<268::aid-jemt3>3.0.co;2-1 · Cited by 42
Sultana, R., Robinson, R. A. S., Di Domenico, F., Abdul, H. M., Clair, D. K. S., Markesbery, W. R., Cai, J., Pierce, W. M., & Butterfield, D. A. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.06.015 · Cited by 41
“The evidence of Aβ being a key player in AD pathogenesis was proposed principally based on familial Alzheimer disease (FAD) individuals, who have autosomal dominant mutations in amyloid precursor protein (APP) or presenilin (PS) genes 1 and 2 [6, 7], a mutation in PS-1 being more aggressive.”
Ringman, J. M., Coppola, G., Elashoff, D., Rodriguez-Agudelo, Y., Medina, L. D., Gylys, K., Cummings, J. L., & Cole, G. M. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000335729 · Cited by 42
Lysosomal Fusion Dysfunction as a Unifying Hypothesis for Alzheimer's Disease Pathology
Funk, K. E., & Kuret, J. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/752894 · Cited by 41
Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes
Miners, J. S., Palmer, J. C., Tayler, H. M., Palmer, L. E., Ashby, E. L., Kehoe, P. G., & Love, S. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00238 · Cited by 50
“Other studies showed significant association between ACE variants and Aβ1−42 concentration or the Aβ1−42:Aβ1−40 ratio in the CSF (Lehmann et al., 2005; Kauwe et al., 2009).”
BackgroundArachidonic or Docosahexaenoic Acid Diet Prevents Memory Impairment in Tg2576 Mice
Hosono, T., Mouri, A., Nishitsuji, K., Jung, C., Kontani, M., Tokuda, H., Kawashima, H., Shibata, H., Suzuki, T., Nabehsima, T., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150341 · Cited by 43
“A high A 42/A 40 ratio is a major determinant for AD development in familial AD with presenilin mutations [60–62].”
BackgroundPhysical activity and beta-amyloid pathology in Alzheimer's disease: A sound mind in a sound body
Ebrahimi, K., Majdi, A., Baghaiee, B., Hosseini, S. H., & Sadigh‐Eteghad, S. (2017) · EXCLI journal · doi:10.17179/excli2017-475 · Cited by 47
Modulating Effect of Diet on Alzheimer’s Disease
Fernández-Sanz, P., Ruiz-Gabarre, D., & García‐Escudero, V. (2019) · Diseases · doi:10.3390/diseases7010012 · Cited by 43
“It has been related to mutations in the genes that encode presenilin 1 and 2 (PS1 and PS2), resulting in enhanced processing of amyloid precursor protein (APP) by β- and γ-secretases, responsible for the amyloidogenic route [9,10], or in the gene that encodes APP itself [11].”
BackgroundTajbakhsh, A., Read, M., Barreto, G. E., Ávila-Rodriguez, M., Gheibi-Hayat, S. M., & Sahebkar, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173873 · Cited by 41
von der Haar, T., Jossé, L., Wright, P. D., Zenthon, J., & Tuite, M. F. (2007) · Neurodegenerative Diseases · doi:10.1159/000101838 · Cited by 51
Rudzinski, L. A., Fletcher, R. M., Dickson, D. W., Crook, R., Hutton, M. L., Adamson, J. L., & Graff‐Radford, N. R. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181732399 · Cited by 43
Self-citationMolecular and Cellular Basis for Anti-Amyloid Therapy in Alzheimer Disease
Gandy, S., Martins, R. N., & Buxbaum, J. D. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200310000-00011 · Cited by 42
Bader Lange, M. L., St. Clair, D., Markesbery, W. R., Studzinski, C. M., Murphy, M. P., & Butterfield, D. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.01.004 · Cited by 40
“Familial Alzheimer disease (FAD) is caused by autosomal dominant mutations in the amyloid precursor protein (APP) or presenilin (PS) genes 1 and2 (Citron et al., 1992; Scheuner et al., 1996; Sturchler-Pierrat et al., 1997), a mutation in PS-1 being more aggressive.”
BackgroundCapelli, E., Torrisi, F., Venturini, L., Granato, M. J. M. G., Fassina, L., Lupo, G. F. D., & Ricevuti, G. (2017) · Journal of Healthcare Engineering · doi:10.1155/2017/2530270 · Cited by 41
Presenilin 1 Independently Regulates β-Catenin Stability and Transcriptional Activity
Killick, R., Pollard, C. C., Asuni, A. A., Mudher, A. K., Richardson, J. C., Rupniak, H. T., Sheppard, P. W., Varndell, I. M., Brion, J.-P., Levey, A. I., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108332200 · Cited by 41
Plasma β‐Amyloid Peptide, Transforming Growth Factor‐β1, and Risk for Cerebral Amyloid Angiopathy
Greenberg, S. M., CHO, H., O’Donnell, H. C., Rosand, J. M., Segal, A. Z., Younkin, L. H., Younkin, S. G., & Rebeck, G. W. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06361.x · Cited by 45
Self-citationDetection and quantitation of cellularly derived amyloid β peptides by immunoprecipitation‐HPLC‐MS
Clarke, N. J., Tomlinson, A. J., Ohyagi, Y., Younkin, S. G., & Naylor, S. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00706-6 · Cited by 43
Self-citationToward Alzheimer Therapies Based on Genetic Knowledge
Hardy, J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103607 · Cited by 44
Self-citationUchida, K. (2022) · Cells · doi:10.3390/cells11050919 · Cited by 43
Glymphatic System Dysfunction in Central Nervous System Diseases and Mood Disorders
Zhang, D., Li, X., & Li, B. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.873697 · Cited by 49
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.